Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study

NCT02717949 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped failure to recruit

Conditions

Liver Disease

Interventions

DRUG: sofosbuvir/ledipasvir
DRUG: sofosbuvir
DRUG: Ribavirin

Sponsor

University of Texas Southwestern Medical Center

Collaborators

[object Object]
[object Object]